| Source: |
| Type: |
| Tumor cell migration is a critical process in cancer progression and metastasis, which is the spread of cancer cells from the primary tumor to distant sites in the body. |
| 5250- | Ba, | Exploring baicalein: A natural flavonoid for enhancing cancer prevention and treatment |
| - | Review, | Var, | NA |
| 5251- | Ba, | The Fascinating Effects of Baicalein on Cancer: A Review |
| - | Review, | Var, | NA |
| 2473- | BA, | Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B | - | in-vitro, | Lung, | H460 |
| 2606- | Ba, | Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma |
| - | Review, | HCC, | NA |
| 2615- | Ba, | The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways |
| - | Review, | Var, | NA |
| 2289- | Ba, | Rad, | Baicalein Inhibits the Progression and Promotes Radiosensitivity of Esophageal Squamous Cell Carcinoma by Targeting HIF-1A |
| - | in-vitro, | ESCC, | KYSE150 |
| 5536- | BBM, | Regulation of Cell-Signaling Pathways by Berbamine in Different Cancers |
| - | Review, | Var, | NA |
| 5540- | BBM, | Berbamine Inhibits Cell Proliferation and Migration and Induces Cell Death of Lung Cancer Cells via Regulating c-Maf, PI3K/Akt, and MDM2-P53 Pathways |
| - | vitro+vivo, | NSCLC, | NA |
| 5555- | BBM, | Berbamine inhibits cell proliferation and invasion by increasing FTO expression in renal cell carcinoma cells |
| - | vitro+vivo, | RCC, | NA |
| 1398- | BBR, | Berberine inhibits the progression of renal cell carcinoma cells by regulating reactive oxygen species generation and inducing DNA damage |
| - | in-vitro, | Kidney, | NA |
| 1392- | BBR, | Based on network pharmacology and experimental validation, berberine can inhibit the progression of gastric cancer by modulating oxidative stress |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | MKN45 |
| 2700- | BBR, | Cell-specific pattern of berberine pleiotropic effects on different human cell lines |
| - | in-vitro, | GBM, | U343 | - | in-vitro, | GBM, | MIA PaCa-2 | - | in-vitro, | Nor, | HDFa |
| 2702- | BBR, | The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1 |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1975 |
| 2709- | BBR, | Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α |
| - | in-vitro, | HCC, | HepG2 |
| 2711- | BBR, | Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2678- | BBR, | Berberine as a Potential Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 2682- | BBR, | Berberine Inhibited Growth and Migration of Human Colon Cancer Cell Lines by Increasing Phosphatase and Tensin and Inhibiting Aquaporins 1, 3 and 5 Expressions |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | HCT116 |
| 1102- | BBR, | Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells |
| - | in-vitro, | Melanoma, | B16-BL6 |
| 5182- | BBR, | Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-κB, u-PA and MMP-2 and -9 |
| - | in-vitro, | SCC, | SCC4 |
| 5180- | BBR, | Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth |
| - | in-vitro, | NSCLC, | NA |
| 5638- | BCA, | Investigating the Anticancer Potential of Biochanin A in KB Oral Cancer Cells Through the NFκB Pathway |
| - | in-vitro, | Oral, | NA |
| 5591- | BetA, | Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment |
| - | Review, | BC, | NA |
| 2719- | BetA, | Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential |
| - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Bladder, | UMUC3 | - | in-vitro, | Bladder, | 5637 |
| 2730- | BetA, | Betulinic acid induces autophagy-dependent apoptosis via Bmi-1/ROS/AMPK-mTOR-ULK1 axis in human bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 2757- | BetA, | Betulinic Acid Inhibits Glioma Progression by Inducing Ferroptosis Through the PI3K/Akt and NRF2/HO-1 Pathways |
| - | in-vitro, | GBM, | U251 |
| 2738- | BetA, | Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | NA, | NA |
| 2741- | BetA, | Betulinic acid triggers apoptosis and inhibits migration and invasion of gastric cancer cells by impairing EMT progress |
| - | in-vitro, | GC, | SNU16 | - | in-vitro, | GC, | NCI-N87 | - | in-vivo, | NA, | NA |
| 2742- | BetA, | Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | BC, | 4T1 | - | in-vitro, | BC, | MCF-7 |
| 2756- | BetA, | Betulinic acid inhibits growth of hepatoma cells through activating the NCOA4-mediated ferritinophagy pathway |
| - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | H1299 |
| 5515- | BEV, | Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. |
| - | Review, | Var, | NA |
| 5726- | BF, | Bufalin exerts antitumor effects in neuroblastoma via the induction of reactive oxygen species-mediated apoptosis by targeting the electron transport chain |
| - | Review, | neuroblastoma, | SK-N-BE |
| 5715- | BF, | Bufalin for an innovative therapeutic approach against cancer |
| - | Review, | Var, | NA |
| 5689- | BJ, | Brucea javanica oil inhibited the proliferation, migration, and invasion of oral squamous carcinoma by regulated the MTFR2 pathway |
| - | vitro+vivo, | Oral, | CAL27 |
| 5481- | BM, | Therapeutic potential of Bacopa monnieri extracts against hepatocellular carcinoma through in-vitro and computational studies |
| - | in-vitro, | HCC, | HepG2 |
| 5477- | BM, | The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell Migration and Tubulogenesis and Induces Apoptosis. |
| - | in-vitro, | Var, | NA |
| 5476- | BM, | In Vitro Synergistic Inhibition of HT-29 Proliferation and 2H-11 and HUVEC Tubulogenesis by Bacopaside I and II Is Associated with Ca2+ Flux and Loss of Plasma Membrane Integrity |
| - | vitro+vivo, | CRC, | HT29 |
| 5684- | BML, | Bromelain mediates apoptosis in HeLa cells via ROS-independent pathway |
| - | in-vitro, | Cerv, | HeLa |
| 696- | Bor, | Nothing Boring About Boron |
| - | Review, | Var, | NA |
| 702- | Bor, | GEN, | SeMet, | Rad, | Evaluation of ecological and in vitro effects of boron on prostate cancer risk (United States) |
| - | Analysis, | NA, | NA |
| 709- | Bor, | Cellular changes in boric acid-treated DU-145 prostate cancer cells |
| - | in-vitro, | Pca, | DU145 |
| 722- | Bor, | Boric acid as a promising agent in the treatment of ovarian cancer: Molecular mechanisms |
| - | in-vitro, | Ovarian, | MDAH-2774 |
| 2768- | Bos, | Boswellic acids as promising agents for the management of brain diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 1416- | Bos, | Anti-cancer properties of boswellic acids: mechanism of action as anti-cancerous agent |
| - | Review, | NA, | NA |
| 5691- | BRU, | Brusatol Inhibits Proliferation, Migration, and Invasion of Nonsmall Cell Lung Cancer PC-9 Cells |
| - | in-vitro, | Lung, | PC9 | - | in-vitro, | Lung, | H1975 |
| 5698- | BRU, | Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma |
| - | in-vitro, | HCC, | NA |
| 5700- | BRU, | Brusatol modulates the Nrf2/GCLC pathway to enhance ferroptosis in the treatment of oral squamous cell carcinoma |
| - | in-vitro, | Oral, | CAL27 |
| 5709- | Brut, | Mechanisms Underlying the Anti-Tumoral Effects of Citrus bergamia Juice |
| - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 2047- | Buty, | Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells |
| - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Nor, | SV-HUC-1 | - | in-vitro, | Bladder, | 5637 | - | in-vivo, | NA, | NA |
| 1207- | CA, | PacT, | Caffeine inhibits the anticancer activity of paclitaxel via down-regulation of α-tubulin acetylation |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa |
| 1651- | CA, | PBG, | Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:326 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid